Saturday 17 October 2026 Export CGC’s income statement to Excel — free account

Canopy Growth Corporation

CGC Healthcare Drug Manufacturers Specialty & Generic

Canopy Growth Corporation’s revenue for fiscal 2026 (year ended March 2026) was $206.0 million, up 6.55% from fiscal 2025. In the quarter to June 2026, revenue grew 12.4%, EPS grew 87.5%, free cash flow fell 117.6% and total debt fell 18.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, operating cash flow growth for three.

0.71 0.03 −4.05%

Follow CGC

Alert me

Market cap: $311.2M
P/E: 0.0×
Fwd P/E: −5.6×
Dividend yield: —
F-score: 5/9
Altman Z: −13.21
Beneish M: −3.49
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.39

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	—	1	4	—	—	7	—	2	5	—

Insider Ownership 0.38%

Capital & Financial Ratios $m

Market Cap 311.15

Revenue 212.47

Net Income (170.80)

Free Cash Flow (60.22)

Net Debt (73.30)

Current Ratio 3.04

Debt/Equity 0.35

P/E ratio 0.00

Fwd P/E (5.63)

P/S ratio 1.41

P/B ratio 0.60

Past 5Y EPS Growth —

This Y EPS Growth 83.67%

Next Y EPS Growth 23.26%

Next Y revenue growth 16.47%

Next 5Y EPS Growth 55.24%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 13.35%

10-year low 10-year high

P/B against its own 10 years 10.88%

10-year low 10-year high

EV/Sales against its own 10 years 1.63%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	156	99	268	247
Receivables	38	38	26	31
Inventory	57	69	80	78
Other	—	—	—	—
	275	212	383	366

	2024	2025	2026	Q'26
Payables	21	19	25	21
ST’ Debt	77	3	12	21
Other	36	18	47	45
	174	68	115	120

Compound Annual Growth %

	10y	5y	3y
Sales	35.59%	(13.04%)	(12.24%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	18.08%	(28.18%)	(4.24%)

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	59	—	—	—	—
’26	52	48	53	52	206
’25	48	46	53	45	193
’24	81	52	58	30	220
’23	86	90	75	54	305
’22	111	104	112	88	415
’21	80	102	117	116	414

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(18)	—	—	—	—
’26	(7)	(13)	(12)	(14)	(46)
’25	(38)	(40)	(17)	(24)	(119)
’24	(111)	(59)	(21)	(18)	(209)
’23	(110)	(100)	(98)	(114)	(422)
’22	(135)	(65)	(133)	(103)	(435)
’21	(86)	(125)	(72)	(71)	(353)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(19)	—	—	—	—
’26	(9)	(14)	(13)	(14)	(50)
’25	(37)	(41)	(18)	(27)	(124)
’24	(50)	(8)	(22)	(17)	(98)
’23	(112)	(93)	(100)	(114)	(419)
’22	(152)	(76)	(116)	(107)	(452)
’21	(132)	(138)	(86)	(80)	(436)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.02)	—	—	—	—
’26	(0.16)	0.00	(0.13)	(0.29)	(0.64)
’25	(1.17)	(1.08)	(0.79)	(1.00)	(4.00)
’24	(0.50)	(3.20)	(1.92)	(0.76)	(6.52)
’23	(41.00)	(3.60)	(4.00)	(9.50)	(53.50)
’22	6.80	(0.20)	(2.20)	(11.50)	(6.20)
’21	(2.20)	(0.70)	(18.60)	(14.60)	(35.60)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	49.00	167.37	138.10	90.00	85.25	20.90	3.46	2.65	0.77	0.69	Analyst estimates 2027–2029 Powerpack
	High	263.70	592.50	527.40	295.20	564.97	96.40	32.20	14.92	3.07	1.51
People
People	Employees	546	1,033	3,200	4,434	3,259	3,151	1,621	1,029	960	1,128
	Revenue/emp, $m	0.14	0.13	0.06	0.07	0.13	0.13	0.19	0.21	0.20	0.18
Income, $m
Income, $m	Revenue	76	139	201	300	414	415	305	220	193	206
	Gross margin, %	37.65	41.62	33.64	(7.95)	12.25	(37.10)	(25.85)	27.22	29.56	24.48
	EBT	(13)	(41)	(501)	(1,135)	(1,276)	(263)	(2,507)	(349)	(429)	(190)
	EBT margin, %	(17.07)	(29.48)	(248.82)	(378.43)	(308.05)	(63.31)	(822.61)	(158.63)	(221.94)	(92.37)
	Net income	(13)	(42)	(511)	(1,043)	(1,266)	(256)	(2,504)	(359)	(434)	(190)
	Depreciation	5	16	36	94	96	91	64	39	31	26
Per share, $
Per share, $	Revenue	6.40	7.84	7.54	8.61	11.15	10.61	6.57	2.95	1.80	0.69
	Earnings	(1.10)	(3.10)	(19.30)	(28.30)	(35.60)	(6.20)	(53.50)	(6.52)	(4.00)	(0.64)
	Cash flow	(1.73)	(3.59)	(14.86)	(16.69)	(9.50)	(11.13)	(9.10)	(2.79)	(1.11)	(0.15)
	Capex	(1.89)	(7.84)	(19.49)	(15.59)	(2.24)	(0.42)	0.05	1.49	(0.04)	(0.01)
	Free cash flow	(3.62)	(11.42)	(34.34)	(32.28)	(11.74)	(11.55)	(9.05)	(1.31)	(1.15)	(0.17)
	Book value	39.36	54.71	206.67	110.34	71.10	73.28	12.40	4.96	3.26	1.69
	Shares, m	12	18	27	35	37	39	46	75	108	298
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	31.64	56.31	16.74	28.73	7.15	2.66	2.56	0.51	1.37
	P/B	2.51	4.54	2.06	1.31	4.51	1.03	1.41	1.52	0.28	0.56
	EV/Sales	0.00	29.88	42.80	12.90	27.40	7.37	3.93	3.86	1.12	0.90
	EV/FCF	0.00	(20.52)	(9.40)	(3.44)	(26.02)	(6.77)	(2.86)	(8.69)	(1.76)	(3.65)
Cash, $m
Cash, $m	Operating cash flow	(21)	(64)	(397)	(581)	(353)	(435)	(422)	(209)	(119)	(46)
	Capex	(22)	(139)	(520)	(543)	(83)	(17)	2	111	(5)	(4)
	Free cash flow	(43)	(203)	(917)	(1,124)	(436)	(452)	(419)	(98)	(124)	(50)
Balance, $m
Balance, $m	Working capital	122	304	3,550	1,612	1,936	1,216	207	101	144	269
	Total debt	8	7	721	350	1,200	1,197	989	443	219	169
	Net debt	(70)	(245)	(2,720)	(1,152)	(551)	93	388	286	119	(99)
	Shareholders’ equity	468	970	5,518	3,840	2,642	2,868	575	371	350	505
Returns, %
Returns, %	ROA	(4.90)	(6.71)	(13.44)	(16.82)	(25.61)	(5.00)	(78.42)	(34.69)	(52.96)	(25.90)
	ROIC	(1.82)	(5.63)	(9.82)	(29.17)	(28.17)	(18.23)	(139.89)	(16.12)	(11.21)	(18.00)
	ROE	(4.49)	(7.63)	(16.10)	(21.23)	(40.80)	(8.75)	(144.08)	(103.01)	(119.21)	(44.51)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KMDA Kamada Ltd.	$451.7M	20.4×	— (loss-making)	+22.72% (above 0%: growing)	+23.08% (above 0%: growing)	+165.71% (above 0%: growing)	40.91%	17.32%	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)
ANIK Anika Therapeutics Inc.	$276.9M	— (loss-making)	— (loss-making)	+15.56% (above 0%: growing)	n/m	+61.58% (above 0%: growing)	65.15%	9.06%	Compare
ACB Aurora Cannabis Inc.	$265.8M	— (loss-making)	— (loss-making)	−31.15% (below 0%: shrinking)	n/m	−293.56% (below 0%: shrinking)	52.73%	(12.92%)	Compare
BIOA BioAge Labs, Inc.	$245.6M	— (loss-making)	— (loss-making)	+1.62% (above 0%: growing)	n/m	+2.68% (above 0%: growing)	100.00%	(1,196.78%)	Compare
LFCR Lifecore Biomedical, Inc.	$244.1M	— (loss-making)	— (loss-making)	−6.25% (below 0%: shrinking)	n/m	−117.03% (below 0%: shrinking)	35.34%	7.51%	Compare
SIGA Siga Technologies Inc.	$229.2M	— (loss-making)	28.7×	−49.45% (below 0%: shrinking)	−66.00% (below 0%: shrinking)	−75.95% (below 0%: shrinking)	57.17%	33.91%	Compare
Median of peers	$271.4M	—	—	+8.59%	—	−22.50%	54.95%	(2.71%)

All 86 Drug Manufacturers Specialty & Generic stocks →